Comparison of screening for pre-eclampsia at 31-34 weeks' gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF

Objective: To estimate the patient-specific risk of preeclampsia (PE) at 31-34 weeks’ gestation by a combination of maternal characteristics and medical history with multiple of the median (MoM) values of serum placental growth factor (PLGF) and serum soluble fms-like tyrosine kinase-1 (sFLT-1) and compare the performance of screening to that achieved by the sFLT-1 to PLGF ratio.

Methods: This was a prospective observational study in women attending for a third-trimester ultrasound scan at 31-34 weeks as part of routine pregnancy care. We estimated the performance of screening of PE with delivery within four weeks of assessment (PE at <4 weeks) and PE from four weeks after assessment and up to 40 weeks’ gestation (PE at 4w-40GW) in screening by the sFLT-1 to PLGF ratio and by a to PLGF ratio and by a method utilizing Bayes theorem to combine maternal factors and MoM values of sFLT-1 and PLGF. The significance of difference in performance of screening between the method utilising Bayes theorem and that of the sFLT-1 to PLGF ratio was assessed by comparison of the areas under the receiver operating characteristic curves (AUROC).

Results: The study population of 8,063 singleton pregnancies included 231 (2.9%) that subsequently developed PE. In the prediction of delivery with PE at <4 weeks the performance of the method utilising Bayes theorem was similar to that of the sFLT-1 to PLGF (AUROC: 0.987, 95%CI 0.979-0.995 vs. 0.988, 95%CI: 0.981-0.994; p=0.961). and at fixed fixed screen positive rate (SPR) of 3.9% the detection rate (DR) was 87.1% for both methods. In contrast, the performance of screening for delivery with PE at 4w-40GW was better with the method utilising Bayes theorem than with the sFLT-1 to PLGF ratio
(AUROC: 0.884, 95%CI 0.854-0.914 vs. 0.818, 95%CI: 0.775--0.860 ; p<0.0001) and at total fixed SPR of 25.7% the DRs were 84.4% vs. 73.0%.

Conclusion: At 31-34 weeks’ gestation the performance of screening for PE at <4 weeks from assessment by the method utilising Bayes theorem is similar to that of the sFLT-1 to
PLGF ratio, but the former is superior to the latter in prediction of PE >>4 weeks.

1. Maynard SE, Min JY, Merchan J, Maynard SE, Min JY, Merchan J, Lim KH,
Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH,
Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1
(sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in
pre-eclampsia. J Clin Invest 2003; 111: 649–658.
2. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF,
Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA.
Circulating angiogenic factors and the risk of pre-eclampsia. NEnglJMed2004;
350: 672–683.
3. Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto E,
Dong Z, Tarca A, Gaurav B, Hassan SS. Maternal plasma concentrations of
angiogenic/anti-angiogenic factors are of prognostic value in patients presenting
to the obstetrical triage area with the suspicion of pre-eclampsia. J Matern Fetal
Neonatal Med 2011; 24: 1187–1207.
4. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, Calda P,
Holzgreve W, Galindo A, Engels T, Denk B, Stepan H. The sFlt-1/PlGF ratio in
different types of hypertensive pregnancy disorders and its prognostic potential in
preeclamptic patients. Am J Obstet Gynecol 2012; 206: 58.e1–8.
5. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH,
Wenger JB, Thadhani R, Karumanchi SA. Angiogenic factors and the risk of adverse
outcomes in women with suspected pre-eclampsia. Circulation 2012; 125: 911–919.
6. Ohkuchi A, Hirashima C, Takahashi K, Suzuki H, Matsubara S, Suzuki M: Onset
threshold of the plasma levels of soluble fms-like tyrosine kinase 1/placental growth
factor ratio for predicting the imminent onset of pre-eclampsia within 4 weeks after
blood sampling at 19–31 weeks of gestation. Hypertens Res 2013; 36: 1073–1080.
7. Lai J, Garcia-Tizon Larroca S, Peeva G, Poon LC, Wright D, Nicolaides KH.
Competing risks model in screening for pre-eclampsia by serum placental growth
factor and soluble fms-like tyrosine kinase-1 at 30–33 weeks’ gestation. Fetal Diagn
Ther 2014; 35: 240–248.
8. Tsiakkas A, Saiid Y, Wright A, Wright D, Nicolaides KH. Competing risks model
in screening for pre-eclampsia by maternal factors and biomarkers at 30–34 weeks’
gestation. Am J Obstet Gynecol 2016; 215: 87.e1–17.
9. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstr
¨
om M, Olovsson M,
Brennecke SP, Stepan H, Allegranza D, Dilba P, Schoedl M, Hund M, Verlohren S.
Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Pre-eclampsia.
NEnglJMed2016; 374: 13–22.
10. Wright D, Syngelaki A, Akolekar R, Poon LC, Nicolaides KH. Competing risks
model in screening for pre-eclampsia by maternal characteristics and medical history.
Am J Obstet Gynecol 2015; 213: 62.e1–10.
11. Wright D, Akolekar R, Syngelaki A, Poon LC, Nicolaides KH. A competing risks
model in early screening for pre-eclampsia. Fetal Diagn Ther 2012; 32: 171–178.
12. O’Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides
KH. Competing risks model in screening for preeclampsia by maternal factors and
biomarkers at 11 –13 weeks’ gestation. Am J Obstet Gynecol 2016; 214: 103.e1– 12.
13. O’Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, Wright A, Akolekar
R, Cicero S, Janga D, Jani J, Molina FS, De Paco Matallana C, Papantoniou N,
Persico N, Plasencia W, Singh M, Nicolaides KH. Accuracy of competing risks model
in screening for preeclampsia by maternal factors and biomarkers at 11–13 weeks’
gestation. Ultrasound Obstet Gynecol 2017. doi: 10.1002/uog.17399.
14. Tsiakkas A, Duvdevani N, Wright A, Wright D, Nicolaides KH. Serum placental
growth factor in the three trimesters of pregnancy: effects of maternal characteristics
and medical history. Ultrasound Obstet Gynecol 2015; 45
: 591–598.
15. Tsiakkas A, Duvdevani N, Wright A, Wright D, Nicolaides KH. Serum soluble
fms-like tyrosine kinase-1 in the three trimesters of pregnancy: effects of
maternal characteristics and medical history. Ultrasound Obstet Gynecol 2015; 45:
584–590.
16. Wright D, Dragan I, Syngelaki A, Akolekar R, Nicolaides KH. Proposed clinical
management of pregnancies after combined screening for pre-eclampsia at 30–34
weeks’ gestation. Ultrasound Obstet Gynecol 2017; 49: 194–200.
17. Robinson HP, Fleming JE. A critical evaluation of sonar crown rump length
measurements. Br J Obstet Gynaecol 1975; 82: 702–710.
18. Snijders RJ, Nicolaides KH. Fetal biometry at 14–40 weeks’ gestation. Ultrasound
Obstet Gynecol 1994; 4: 34–48.
19. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The
classification and diagnosis of the hypertensive disorders of pregnancy: Statement
from the international society for the study of hypertension in pregnancy (ISSHP).
Hypertens Pregnancy 2001; 20: IX–XIV.
20. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or
more correlated receiver operating characteristic curves: a nonparametric approach.
Biometrics 1988; 44: 837–845.
21. R Development Core Team. R. A language and environment for statistical
computing. R Foundation for Statistical Computing, Vienna, Austria. 2011; ISBN
3-900051-07-0. http://www.R-project.org/.
22. Tsiakkas A, Cazacu R, Wright A, Wright D, Nicolaides KH. Maternal serum placental
growth factor at 12, 22, 32 and 36 weeks’ gestation in screening for pre-eclampsia.
Ultrasound Obstet Gynecol 2016; 47: 472–477.
23. Tsiakkas A, Mendez O, Wright A, Wright D, Nicolaides KH. Maternal serum soluble
fms-like tyrosine kinase-1 at 12, 22, 32 and 36 weeks’ gestation in screening for
pre-eclampsia. Ultrasound Obstet Gynecol 2016; 47: 478–483.
24. Nicolaides KH. Turning the pyramid of prenatal care. Fetal Diagn Ther 2011; 29:
183–196.